港股異動丨石藥集團(1093.HK)漲近4% 機構唱多
格隆匯6月2日丨石藥集團(1093.HK)漲近4%,報16.28港元,總市值1015億港元。大摩發表研究報告,指基石藥業股價會於未來30日上升,機率為70-80%,目標價16.3港元,評級增持。該行指,公司合作伙伴Blueprint Medicines公佈用於RET基因融合非小細胞肺癌的新藥pralsetinib第一二期的研究關鍵數據,並進行臨牀試驗,預期可於第四季獲美國藥監局批准。基石藥業擁有pralsetinib中國使用權,預期於今年第三季遞交申請。野村發研報指,石藥集團今年首季業績強勁勝市場預期。管理層預期,隨着3月份醫院的問診服務恢復,藥物銷售增長會進一步加速。該行維持其“買入”評級,目標價24港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.